{
    "organizations": [],
    "uuid": "87a9307e6e00fae5fdc83b34c98f710e9f17ba3a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-roche-holding-ag-ceo-says-no-chang/brief-roche-holding-ag-ceo-says-no-change-in-ma-strategy-idUSFWN1PR08O",
    "ord_in_thread": 0,
    "title": "BRIEF-Roche Holding AG CEO Says No Change In M&A Strategy",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 1 (Reuters) - Roche Holding Ag:\n* CEO SAYS CONFIDENT NEW DRUGS CAN COMPENSATE FOR OLDER DRUGS LOSING PATENT PROTECTION\n* CEO SAYS ROCHE CAN POTENTIALLY SLIGHTLY GROW BUSINESS DESPITE BIOSIMILARS, INTENDS TO KEEP ‘STRONG MARGINS WHICH WE ENJOY TODAY’\n* CEO SAYS HAS INCREASING CONFIDENCE OVER RECENT PAST THAT ROCHE CAN COMPENSATE FOR BIOSIMILARS\n* CEO SAYS IMPAIRMENT CHARGES ON SEVERAL ITEMS INCLUDING ESBRIET, DUE TO “MODERATE UPTAKE” IN EARLIER LINES OF TREATMENT\n* CEO SAYS VERY CONFIDENT TECENTRIQ TO PLAY LEADING ROLE IN VARIOUS CANCER TYPES\n* CEO SAYS NO CHANGE IN M&A STRATEGY, LOOKING FOR BOLT-ON OPPORTUNITIES TO COMPLEMENT PORTFOLIO Source text for Eikon: Further company coverage: (Reporting by John Miller)\n ",
    "published": "2018-02-01T14:57:00.000+02:00",
    "crawled": "2018-02-02T13:06:39.061+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "roche",
        "holding",
        "ag",
        "ceo",
        "say",
        "confident",
        "new",
        "drug",
        "compensate",
        "older",
        "drug",
        "losing",
        "patent",
        "protection",
        "ceo",
        "say",
        "roche",
        "potentially",
        "slightly",
        "grow",
        "business",
        "despite",
        "biosimilars",
        "intends",
        "keep",
        "strong",
        "margin",
        "enjoy",
        "today",
        "ceo",
        "say",
        "increasing",
        "confidence",
        "recent",
        "past",
        "roche",
        "compensate",
        "biosimilars",
        "ceo",
        "say",
        "impairment",
        "charge",
        "several",
        "item",
        "including",
        "esbriet",
        "due",
        "moderate",
        "uptake",
        "earlier",
        "line",
        "treatment",
        "ceo",
        "say",
        "confident",
        "tecentriq",
        "play",
        "leading",
        "role",
        "various",
        "cancer",
        "type",
        "ceo",
        "say",
        "change",
        "strategy",
        "looking",
        "opportunity",
        "complement",
        "portfolio",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "reporting",
        "john",
        "miller"
    ]
}